Population: General population

Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population

Jiménez-Nogueira

Spain
|
2020-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Geismar

United Kingdom
|
2020-2022
  • General population
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • Household
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

Okay

Türkiye
|
2021-2023
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Rupp

Switzerland
|
2009-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection

Ezpeleta

Spain
|
2023-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Ocana de Sentuary

France
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Coma

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Coma 2

Spain
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Primary care
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Costantino

Italy
|
2022-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

Perramon-Malavez

Spain
|
2023-2024
  • General population
  • Infants (<1 year)
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

FIDO

United Kingdom Ireland
|
2022-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

Santus

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19